In 2006, the creation of sofie launched the aspiration of having a multifaceted approach to expand the reach of pet products for patients with advanced imaging needs This was further realized in 2017 with the addition of a radiopharmacy network with global distribution capabilities. Transparency in coverage (tic) regulations requires health insurers and group health plans to post their provider link on company websites View sofie’s link here view our privacy policy Our team works alongside our pharma and academic partners to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease. We are currently performing data analysis and behind the scenes planning for phase 3 is well underway.
Our product lines include fdg, pylarify, neuraceq, and other clinical trial products. With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value theranostic intellectual property, sofie is poised to deliver on the promise of radiopharmaceuticals.
OPEN
